Log in to search using one of your social media accounts:

 

The T cell in Myeloma
An active role for the immune system in controlling the malignant plasma cell clone in myeloma has been postulated for many years. The clinical states of monoclonal gammopathy of undetermined significance, plateau phase disease and smoldering myeloma all suggest that a significant host-tumor interaction is taking place. The fundamental role of the cytotoxic T cell in tumor elimination and control has been exemplified by the dramatic efficacy of adoptive T cell therapies in many hemopoietic malignancies. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 9, 2016 Category: Hematology Authors: Douglas Joshua, Hayley Suen, Ross Brown, Christian Bryant, P Joy Ho, Derek Hart, John Gibson Tags: Perspective Source Type: research

Polyclonal localized light chain amyloidosis - a distinct entity?
Amyloidosis is a rare disease of protein misfolding that results in the deposition of insoluble fibrils mainly in the extracellular spaces of tissues and organs. There are currently over 30 distinct proteins currently known to cause amyloidosis in humans.1 Any organs can be involved although the most clinically relevant ones are the heart, kidneys, nerves, liver, and gastrointestinal tract.2 Amyloid deposition can be systemic wherein there is involvement of multiple organs (e.g., monoclonal immunoglobulin light chain or AL) or diffuse involvement of an organ like the kidneys (e.g., lysozyme variants or ALys). (Source: Clin...
Source: Clinical Lymphoma, Myeloma and Leukemia - August 9, 2016 Category: Hematology Authors: Aishwarya Ravindran, Karen L. Grogg, David A. Domaas, Ronald S. Go Tags: Case Report Source Type: research

An Evaluation of Treatment Patterns and Outcomes in Newly Diagnosed Elderly Acute Myeloid Leukemia Patients: A Retrospective Analysis of Electronic Medical Records from US Community Oncology Practices
MicroAbstract: This retrospective observational study of data from the US community oncology setting evaluates real-world treatment patterns and outcomes for newly diagnosed, elderly patients with acute myeloid leukemia (AML). The analysis focuses on those patients who did not receive standard induction therapy ( ‘3 + 7’ type regimens). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 9, 2016 Category: Hematology Authors: Esprit Ma, Vijayveer Bonthapally, Anita Chawla, Patrick Lefebvre, Ronan Swords, Marie-H élène Lafeuille, Jonathan Fortier, Bruno Emond, Mei Sheng Duh, Bruce J. Dezube Tags: Original Study Source Type: research

Prognostic Significance of The Cereblon Expression in Multiple Myeloma Patients
Within a personalized treatment approach in multiple myeloma (MM), prognostic significance of the cereblon (CRBN) expression was analysed in 92 newly diagnosed patients. In patients treated with thalidomide based combinations, CRBN expression significantly affected treatment response (p=0.028), and progression free survival (PFS, p=0.017). Implicating treatment outcome, the level of CRBN expression may represent additional prognostic tool in personalized treatment approach. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 9, 2016 Category: Hematology Authors: Jelena Bila, Aleksandra Sretenovic, Jelena Jelicic, Natasa Tosic, Irena Glumac, Marija Dencic Fekete, Darko Antic, Milena Todorovic Balint, Olivera Markovic, Zoran Milojevic, Milica Radojkovic, Goran Trajkovic, Mila Puric, Sonja Pavlovic, Biljana Mihaljev Tags: Original Study Source Type: research

Key Molecular Drivers of Chronic Lymphocytic Leukaemia (CLL)
Chronic lymphocytic leukaemia (CLL) is an adult neoplastic disease of B-cells that is characterised by variable clinical outcomes. While some patients have an aggressive form of the disease and often encounter treatment failure and short survival, others have more stable disease with long-term survival and little or no need for treatment. In the last decade, significant advances have been made in our understanding of the molecular drivers that impact on the natural pathology of CLL. This review describes what is known about these key molecules in the context of their role in tumour pathogenicity, prognosis and therapy. (So...
Source: Clinical Lymphoma, Myeloma and Leukemia - August 9, 2016 Category: Hematology Authors: Suliman A. Alsagaby, Paul Brennan, Chris Pepper Tags: Review Article Source Type: research

Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides
Patients with cutaneous T-cell lymphoma (CTCL) who have cutaneous tumors or folliculotropic disease involvement typically have poor prognoses. Analysis of the pivotal phase 2 trial of romidepsin in relapsed/refractory CTCL showed that single-agent romidepsin induced clinical response or stable disease in the majority of patients with cutaneous tumors and/or folliculotropic disease involvement, supporting its use in these patient populations. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 9, 2016 Category: Hematology Authors: Francine Foss, Madeleine Duvic, Adam Lerner, Joel Waksman, Sean Whittaker Tags: Original Study Source Type: research

Myelomatous Involvement of the Central Nervous System
Myelomatous involvement of the central nervous system (CNS) is an uncommon complication that portends a poor prognosis in patients with multiple myeloma (MM). Limited data exist regarding optimal management of CNS myeloma. In this case-control study, we examine the clinical presentation, diagnosis, treatment and outcomes of CNS myeloma patients compared with a control group of MM patients without CNS involvement, matched by the date of diagnosis and gender. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 9, 2016 Category: Hematology Authors: Jonas Paludo, Utkarsh Painuly, Shaji Kumar, Wilson I. Gonsalves, Vincent Rajkumar, Francis Buadi, Martha Q. Lacy, Angela Dispenzieri, Robert A. Kyle, Michelle L. Mauermann, Arleigh McCurdy, David Dingli, Ronald S. Go, Suzanne Hayman, Nelson Leung, John A. Tags: Original Study Source Type: research

Indolent Lymphomas that Present with Clinically Aggressive Features: A Subset of Low Grade Lymphomas with a Behavior Inconsistent with the Histologic Diagnosis
We have identified a subset of indolent lymphoma whose presentation differs from their expected indolent nature. They present with aggressive features such as high LDH, high SUVs, high Ki-67 (>30%), B symptoms, unusual areas of involvement (bone, pleura, lung). In spite of the fact that histologically they resemble typical indolent NHLs, they functionally behave as aggressive NHLs. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 9, 2016 Category: Hematology Authors: F. Cabanillas, N. Rivera, W.I. Pardo Tags: Original Study Source Type: research

Evaluation of the impact of renal failure on correlation and concordance between two free light chain assays
Measurement of serum free light chains (FLC) is recommended for diagnosis of monoclonal gammopathies. FLC measurements with FreeliteTM (Binding Site) and N-Latex FLC (Siemens) assays were performed on 1215 fresh sera from patients with or without monoclonal gammopathy and renal failure. A good correlation was demonstrated between both assays, but it remained 7.6%-20.8% discordances between the methods related to the FLC-ratio interpretation. In patient ’s follow-up, few discrepancies were observed. Neither of the assays performed better than the other: they provide comparable but not equivalent results, and discrepan...
Source: Clinical Lymphoma, Myeloma and Leukemia - August 9, 2016 Category: Hematology Authors: Caroline Moreau, Brice Autier, Thibault Cavey, Emmanuel Rouger, James Norwood, Claude Bendavid, Martine Escoffre, Martine S ébillot, Olivier Decaux Tags: Original Study Source Type: research

Survival rates of adults with acute lymphoblastic leukemia in a low- income population. A decade of experience at a single institution in M éxico
Adult acute lymphoblastic leukemia has an elevated mortality rate, with little improvement in recent decades. 94 patients treated over ten years in a low-income population were studied. Younger age, elevated high-risk disease and high relapse rate were documented. However, overall survival after complete remission was the same as in industrialized countries. Cure threshold with current treatment approaches has been reached. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 9, 2016 Category: Hematology Authors: Jos é Carlos Jaime-Pérez, Raúl Alberto Jiménez-Castillo, José Luis Herrera-Garza, Homero Gutiérrez-Aguirre, Luis Javier Marfil-Rivera, David Gómez-Almaguer Tags: Original Study Source Type: research

Single-Center Series of Bone-Marrow Biopsy-Defined Large Granular Lymphocyte leukemia; high rates of sustained response to oral methotrexate
39 patients were stringently diagnosed with large granular lymphocyte leukemia. 15 (38%) remain untreated, 13/24 initially treated with prednisolone, overall response rate (ORR) 84.6%, median duration of response (DOR) 13.5 months, 9/24 received oral methotrexate ORR 89%, median DOR 132.7 months. Five received methotrexate following prednisolone failure; all responded. Single agent oral methotrexate results in long responses with minimal toxicity. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 9, 2016 Category: Hematology Authors: Talha Munir, Mark J. Bishton, Ian Carter, Andrew McMillan, Simon O ’Connor, Vishakha Sovani, Andrew P. Haynes, Christopher P. Fox Tags: Original Study Source Type: research

Outcome of patients with therapy-related acute myeloid leukemia with or without an antecedent history of myelodysplasia
Microabstract: The presence of antecedent hematologic disorders at diagnosis of therapy-related acute myeloid leukemia did not affect overall survival. The favorable risk cohort had better relapse-free survival and overall survival as compared to the outcomes of patients in the intermediate and adverse risk cohorts; the relapse-free survival and overall survival did not differ between intermediate and adverse cohorts. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 9, 2016 Category: Hematology Authors: Koji Sasaki, Elias Jabbour, Jorge Cortes, Tapan Kadia, Guillermo Garcia-Manero, Gautam Borthakur, Preetesh Jain, Sherry Pierce, Naval Daver, Koichi Takahashi, Susan O ’Brien, Hagop Kantarjian, Farhad Ravandi Tags: Original Study Source Type: research

Aberrant p15, p16, p53 and DAPK gene methylation in myelomagenesis: clinical and prognostic implications
Microabstract: Aberrant DNA methylation is important in multiple myeloma pathogenesis. Methylation of p15, p16, p53 and DAPK genes was evaluated in bone marrow (94 patients; 8 controls) by methylation-specific polymerase chain reaction. 63% of MM and 39% of MGUS presented ≥1 hypermethylated gene (p (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 9, 2016 Category: Hematology Authors: Catarina Geraldes, Ana Cristina Gon çalves, Emília Cortesão, Marta Isabel Pereira, Adriana Roque, Artur Paiva, Letícia Ribeiro, José Manuel Nascimento-Costa, Ana Bela Sarmento-Ribeiro Tags: Original Study Source Type: research

Increased Hepatic Iron Content Predicts Poor Survival in Patients With Iron Overload Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation
Transfusional iron overload remains a serious problem in alloHSCT setting. Liver is among the most common organs that iron accumulate. The degree of hepatic iron content might be associated with poorer survival in alloHSCT recipients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Serdar Sivgin, Suleyman Baldane, Kemal Deniz, Gokmen Zararsiz, Leylagul Kaynar, Mustafa Cetin, Ali Unal, Bulent Eser Tags: SOHO Supplement 2016 Source Type: research

The Prognostic Significance of Elevated Serum Ferritin Levels Prior to Transplantation in Patients With Lymphoma Who Underwent Autologous Hematopoietic Stem Cell Transplantation (autoHSCT): Role of Iron Overload
Transfusional iron overload (IO) is considered to be a significant problem hematopoietic stem cell transplantation (HSCT) recipients. Patients with IO have poorer outcomes compared to those with normal iron stores. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Serdar Sivgin, Mehmet Fatih Karamustafaoglu, Esra Yildizhan, Gokmen Zararsiz, Leylagul Kaynar, Bulent Eser, Mustafa Cetin, Ali Unal Tags: SOHO Supplement 2016 Source Type: research

Acute Myeloid Leukemia: Past, Present, and Prospects for the Future
Dose intensification of chemotherapy and the combination of a third cytotoxic agent with standard cytarabine and anthracycline-based induction chemotherapy have led to improved outcomes in select groups of patients with acute myeloid leukemia (AML). However, despite some progress in this area, it appears that we might be reaching the limit of cytotoxic chemotherapy for the treatment of AML, especially in older patients and in those with poor-risk features whose disease tends to be relatively chemoresistant. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Nicholas J. Short, Farhad Ravandi Tags: SOHO Supplement 2016 Source Type: research

When to Consider Allogeneic Transplantation in CML
Tyrosine kinase inhibitor (TKI) therapy has radically altered the treatment strategy for chronic myeloid leukemia. Allogeneic transplantation, which over a decade ago was considered the definitive therapy for CML, is now appropriately used in cases where all TKIs are not tolerated, in cases of resistance to TKI therapy, or when the disease progresses from chronic phase to accelerated or blast phase. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Jerald Radich Tags: SOHO Supplement 2016 Source Type: research

Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale
In a phase I dose-escalation study using eltrombopag to treat patients with myelodysplastic syndromes after hypomethylating agents failure, we observed that patients with chronic myelomonocytic leukemia may respond to eltrombopag. However, use in a subset of chronic myelomonocytic leukemia patients may be limited owing to leukocytosis and circulating blasts. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Hanadi Ramadan, Vu H. Duong, Najla Al Ali, Eric Padron, Ling Zhang, Jeffrey E. Lancet, Alan F. List, Rami S. Komrokji Tags: SOHO Supplement 2016 Source Type: research

Adult T-Cell Leukemia/Lymphoma: Rarely Encountered in the United States
We report our experience with adult T-cell leukemia/lymphoma, a rare and aggressive form of T-cell lymphoma, highlighting the clinical characteristics, response to therapy, and outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Christa Roe, Rami Komrokji, Ling Zhang, Samantha Price, Lubomir Sokol Tags: SOHO Supplement 2016 Source Type: research

Is Maintenance Therapy for Everyone?
Although myeloma remains an incurable disease among majority of myeloma patients, the prognosis has significantly improved after the introduction of novel agents. While more agents are being explored for their anti-myeloma activity, the more familiar agents with a better tolerability profile have been tested in the maintenance arena. Lenalidomide and bortezomib so far have shown promise as effective maintenance agents in prolonging PFS, and also OS in some studies. The current review aims at describing the clinical data supporting various maintenance therapies and also at providing some clarity to a few concerns associated...
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Ajay K. Nooka, Sagar Lonial Tags: SOHO Supplement 2016 Source Type: research

Trends in Clinical Investigation for Myelodysplastic Syndromes
Myelodysplastic syndrome (MDS) paradigms have been dramatically changed over the last 10 years by major breakthroughs on both pathophysiologic and therapeutic aspects. It is currently a field of intense clinical investigation as new challenges have emerged in both low-risk and high-risk populations. In low-risk MDS, long-term control of anemia is a major issue, and second-line treatments after failure of erythropoiesis-stimulating agents are warranted. Several promising therapies are available, and there are many open questions on how to select the most adapted agent and/or sequence of agents in a specific individual. (Sou...
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Thomas Prebet, Amer Zeidan Tags: SOHO Supplement 2016 Source Type: research

Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?
The treatment of patients with chronic lymphocytic leukemia (CLL) whose tumor presents the del(17p)/TP53 mutation is a major challenge. Treatment with chemo(immuno)therapy, immunomodulators, or the anti-CD52 monoclonal antibody alemtuzumab produces transient, unsatisfactory responses. Reduced-intensity-conditioning allotransplantation produces sustained progression-free survival and overall survival (40%-60% at 5 years), equivalent to the cure of the disease, even in cases with adverse biomarkers. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Emili Montserrat, Peter Dreger Tags: SOHO Supplement 2016 Source Type: research

Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma
Discovering prognostic factors that simultaneously describe tumor characteristics and improve risk stratification is a priority in cutaneous T-cell lymphoma (CTCL). More than a third of advanced stage CTCL patients in this cohort had detectable cell free plasma Epstein –Barr virus (EBV)-DNA (pEBVd) using quantitative real-time polymerase chain reaction. An increased level of pEBVd was highly concordant with EBV (ie, Epstein–Barr virus RNAs) in tumor tissue and was associated with inferior survival. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Bradley M. Haverkos, Alejandro A. Gru, Susan M. Geyer, Anissa K. Bingman, Jessica A. Hemminger, Anjali Mishra, Henry K. Wong, Preeti Pancholi, Aharon G. Freud, Michael A. Caligiuri, Robert A. Baiocchi, Pierluigi Porcu Tags: SOHO Supplement 2016 Source Type: research

How to Think About Risk in Myeloma
An integral part of myeloma therapy is risk stratification of newly diagnosed patients. This method involves a combination of staging and genetic risk assessment. Although survival has dramatically improved for patients with genetically defined, standard-risk myeloma, those with high-risk disease remain a therapeutic challenge. Current treatment approaches might include the use of combination therapy for induction and maintenance. Future approaches are expected to involve drugs that are “risk agnostic,” such as monoclonal antibodies and immunotherapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Amrita Krishnan Tags: SOHO Supplement 2016 Source Type: research

A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms
Myeloproliferative neoplasms (MPN) in chronic phase that evolve into blast phase (BP) hold a dismal prognosis and represent an urgent unmet clinical need. The mutational landscape of MPN-BP is distinct from de novo acute myeloid leukemia and offers insight into molecular mechanisms contributing to clonal evolution providing potential novel drug targets. A number of retrospective studies have identified patient- and disease-specific variables associated with increased risk of leukemic transformation (LT) of an underlying MPN. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: John Mascarenhas Tags: SOHO Supplement 2016 Source Type: research

Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome
Immunosuppresive therapy in low risk myelodysplastic syndrome can achieve sustained hematologic improvement but is underutilized due to lack of selection criteria. We completed a retrospective analysis of sixty-six patients treated with immunosuppressive therapy to investigate treatment outcome and clinical co-variables that influence response. Overall hematologic improvement was 42%, comparable to other treatment options for lower risk MDS. The response rate was higher in low risk disease, treated early on in the disease process with immunosuppressive therapy as the first line treatment. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Mintallah Haider, Najla Al Ali, Eric Padron, Pearlie Epling-Burnette, Jeffrey Lancet, Alan List, Rami Komrokji Tags: SOHO Supplement 2016 Source Type: research

Management and Outcomes of HIV-Associated Primary Effusion Lymphoma: A Single Center Experience
Primary effusion lymphoma (PEL) is a rare form of lymphoma, primarily seen in individuals who are immunosuppressed. We studied all cases of PEL seen at our institution over a 15-year period and observed that if affected mostly male patients with HIV who were not taking the antiretroviral medication. Newer chemotherapy regimens including the drug bortezomib may be more effective in treating PEL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Arjun Gupta, Shiraj Sen, Eileen Marley, Weina Chen, Harris V. Naina Tags: SOHO Supplement 2016 Source Type: research

Current State of the Art: Management of Higher Risk Myelodysplastic Syndromes
The higher risk myelodysplastic syndrome (MDS) patients, defined by the International Prognostic Scoring System (IPSS) as intermediate-2 or high-risk groups, compromise a third of MDS patients who have an expected survival of less than 1.5 years. Our ability to better define higher risk MDS improved with the proposal of new clinical risk models such as the revised IPSS and by integration of molecular data, including somatic gene mutations. Allogeneic hematopoietic stem-cell transplantation (AHSCT) remains the only curative option. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Rami S. Komrokji Tags: SOHO Supplement 2016 Source Type: research

Successful Nonsurgical Eradication of Invasive Gastric Mucormycosis
We present the case of successful nonsurgical eradication of gastric mucormycosis with combined polyene and azole antifungal agents. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Georges El Hachem, Nabil Chamseddine, Ghada Saidy, Camil Choueiry, Claude Afif Tags: SOHO Supplement 2016 Source Type: research

Bone Marrow Necrosis: An Unusual Initial Presentation of Sickle Cell Anemia
A 25-year-old woman, previously healthy, was referred to our hospital for management of anemia and thrombocytopenia, with a working diagnosis of thrombotic thrombocytopenic purpura. Two weeks before her presentation to us, she had undergone a cesarian section after failure to progress in labor. No complications developed after the delivery, and she had not received any blood transfusions. One week later, she developed a high-grade fever without any localizing symptoms. She was prescribed antipyretics. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Georges El Hachem, Nabil Chamseddine Tags: SOHO Supplement 2016 Source Type: research

Myelodysplastic Syndromes in Adolescent Young Adults: One Institution's Experience
Little is known regarding myelodysplastic syndromes (MDS) in the younger population. This retrospective review reviewed the characteristics, outcomes, and response to treatment in the adolescent and young adult (AYA) population compared to an older population. MDS was found to be rare and more aggressive in AYA. Karyotype was the most important prognostic factor. Allogeneic stem-cell transplantation offered younger patients the best outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Joanna Grabska, Bijal Shah, Damon Reed, Najla Al Ali, Eric Padron, Hanadi Ramadan, Jeffrey Lancet, Alan List, Rami Komrokji Tags: SOHO Supplement 2016 Source Type: research

Selection of Patients With Myelodysplastic Syndrome for Allogeneic Hematopoietic Stem Cell Transplantation
Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative option for patients with myelodysplastic syndrome (MDS). Because MDS predominantly affects an older population, age-associated comorbidities can preclude patients from cure. HSCT is associated with the risk of morbidity and mortality; however, with safer conditioning regimens and improved supportive care, eligible patients with an appropriately matched donor can receive this therapy without exclusion by older age alone. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Asmita Mishra, Claudio Anasetti Tags: SOHO Supplement 2016 Source Type: research

Lymphomatoid Granulomatosis: A Single Institution Experience and Review of the Literature
In this study we present the general characteristics in a single institution. Treatment with rituximab based-chemotherapy was effective with long term responses. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Julio C. Chavez, Jose Sandoval-Sus, Pedro Horna, Samir Dalia, Celeste Bello, Paul Chevernick, Eduardo M. Sotomayor, Lubomir Sokol, Bijal Shah Tags: SOHO Supplement 2016 Source Type: research

Clonal Evolution in Multiple Myeloma
Multiple myeloma (MM) is the second most common hematologic malignancy encountered among patients in the United States. The last decade has seen incremental improvements in the survival of patients with MM. These advances are, to a large extent, attributable to the addition of proteasome inhibitors and immunomodulatory drugs to the armamentarium of treatment options. The adoption of these drug classes was the result of an empiric research paradigm. However, with the application of next generation sequencing technologies, we are now starting to unravel the genomic landscape of MM. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Bita Fakhri, Ravi Vij Tags: SOHO Supplement 2016 Source Type: research

PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia
PDE4 expression control the inflammation which has an essential role in the pathogenesis of myelodysplastic syndromes (MDS). The expression of each isoform of the PDE4 was evaluated, using transcriptomic profiling, from healthy individuals (n = 10) and patients with MDS (n = 24) or chronic myelomonocytic leukemia (n = 19). PDE4 mean expression was generally higher in MDS than in healthy individuals. Higher PDE4 expression seemed to have a possible negative effect on survival and response to hypomethylating agent (P> .05). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Ali N. Chamseddine, Monica Cabrero, Yue Wei, Irene Ganan-Gomez, Simona Colla, Koichi Takahashi, Hui Yang, Zachary S. Bohannan, Guillermo Garcia-Manero Tags: SOHO Supplement 2016 Source Type: research

Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia
We assessed patients with chronic myelogenous leukemia for serum Ca, PO4, bone alkaline phosphatase, N-telopeptide, osteoprotegerin levels and trabecular bone (TBA) in bone marrow (BM) specimens before and after treatment with dasatinib. We identified a significant increase in TBA % in post-dasatinib BM (P = .022). This suggests that dasatinib therapy can increase TBA, without significant changes in bone and mineral metabolism. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Daniela Hoehn, Jorge E. Cortes, L. Jeffrey Medeiros, Elias J. Jabbour, Juliana E. Hidalgo, Rashmi Kanagal-Shamanna, Carlos E. Bueso-Ramos Tags: SOHO Supplement 2016 Source Type: research

Imatinib Intolerance Is Associated With Blastic Phase Development in Philadelphia Chromosome –Positive Chronic Myeloid Leukemia
The overall prognosis of Philadelphia chromosome –positive chronic myeloid leukemia patients is today considered to be good thanks to targeted therapy with tyrosin kinase inhibitors (TKIs). A study of a 86-patient cohort showed a strong association between imatinib intolerance and blastic phase development, opening the question if whether it is perhaps due to a more aggressive form of the disease intrinsically resistant to TKIs. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Jorge Luis Ángeles-Velázquez, Rafael Hurtado-Monroy, Pablo Vargas-Viveros, Silvia Carrillo-Muñoz, Myrna Candelaria-Hernández Tags: SOHO Supplement 2016 Source Type: research

How to Treat Essential Thrombocythemia and Polycythemia Vera
Polycythemia vera and essential thrombocythemia (ET) are chronic myeloproliferative neoplasms associated with thrombotic or hemorrhagic complications, and increased risk of transformation to myelofibrosis and acute myeloid leukemia. The main goal of therapy is aimed at preventing vascular events that are the leading cause of morbidity and mortality in these patients. Accordingly, risk stratification is the basis for deciding when to treat a patient with cytoreductive therapy. The European LeukemiaNet has developed a series of management recommendations for front-line and second-line therapy to provide the optimal treatment...
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Carlos Besses, Alberto Alvarez-Larr án Tags: SOHO Supplement 2016 Source Type: research

Perspectives and Future Directions for Acute Lymphoblastic Leukemia
I will begin with a patient case to highlight some of the major points I will be making. The patient was a 22-year-old man with relapsed precursor B (pre-B) acute lymphoblastic leukemia (ALL) who had presented to my clinic for possible participation in clinical trial S1312: a phase I trial of inotuzumab combined with CVP (cyclophosphamide, vincristine, prednisone). He was diagnosed in July 2012. At that time, fluorescence in situ hybridization studies demonstrated deletion of the Ikaros gene. He was treated with the pediatric-based regimen, C10403. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Anjali S. Advani Tags: SOHO Supplement 2016 Source Type: research

Prognosis of Primary Myelofibrosis in the Genomic Era
Currently, prognostication in primary myelofibrosis (PMF) relies on the International Prognostic Scoring System (IPSS), dynamic IPSS (DIPSS), and DIPSS-plus, which incorporate age, blood counts, constitutional symptoms, circulating blasts, red cell transfusion need, and karyotype. Although the JAK2 V617F mutation was discovered a decade ago and MPL mutations shortly thereafter, it was the recent discovery of CALR mutations in the vast majority of JAK2/MPL-unmutated patients and recognition of the powerful impact of CALR mutations and triple-negative (JAK2/MPL/CALR-negative) status on outcome that set the stage for revision...
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Prithviraj Bose, Srdan Verstovsek Tags: SOHO Supplement 2016 Source Type: research

Immunophenotypic Characterization of Cytogenetic Subgroups in Egyptian Pediatric Patients With B-Cell Acute Lymphoblastic Leukemia
ALL is the most common childhood malignancy and identification of prognostic factors is important for further improvement of the treatment outcome in this fatal disease. Cytogenetic changes and MRD are the most powerful prognostic factors in ALL. We identified significant correlations between some CD markers and cytogenetic subgroups which can be used in MRD monitoring and as potential therapy targets. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Shady Adnan Awad, Mahmoud M. Kamel, Mahmoud A. Ayoub, Ahmed M. Kamel, Essam H. Elnoshokaty, Niveen El Hifnawi Tags: SOHO Supplement 2016 Source Type: research

Editorial Board/Masthead
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Source Type: research

Proceedings of the Third Annual Meeting of the Society of Hematologic Oncology
The Society of Hematologic Oncology (SOHO) is an international society designed specifically for clinicians, research scientists and related health care professionals who specialize in the research and treatment of patients with hematologic malignancies. SOHO's mission is to promote worldwide research and education through the exchange of scientific information. Organized by its founders and world class committees, SOHO is the only international society specific to this field. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Alan F. List, Hagop Kantarjian, Emil J. Freireich Tags: Editorial Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 25, 2016 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 25, 2016 Category: Hematology Source Type: research

FLT3 Inhibitors for Treating Acute Myeloid Leukemia
FLT3 (Fms-like tyrosine kinase 3) inhibitors are tyrosine kinase inhibitors. The first-generation FLT3 inhibitors were developed several years ago and include midostaurin, lestaurtinib, sunitinib, and sorafenib. They are relatively nonspecific for FLT3, with other potential targets that include platelet-derived growth factor receptor, vascular endothelial growth factor receptor, KIT, and Janus kinase 2. The second-generation inhibitors, including quizartinib, crenolanib, PLX3397, and ASP2215, are more potent and selective than the first-generation inhibitors. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 23, 2016 Category: Hematology Authors: Mona Hassanein, Muhamad H. Almahayni, Syed O. Ahmed, Sameh Gaballa, Riad El Fakih Tags: Review Source Type: research

FLT3 inhibitors for treating Acute Myeloid Leukemia
Acute myelogenous leukemia (AML) is a clonal disorder of hematopoietic stem cells caused by acquired and occasionally inherited genetic alterations(1). FLT3 is a tyrosine kinase receptor that plays a role in proliferation and differentiation of hematopoietic stem cells. Constitutive activation of FLT3 by internal tandem duplication (ITD) mutation is a common molecular alteration in AML, occurring in approximately 20% to 30% of AML patients who have a comparatively poor clinical outcome and increased relapse rate(2). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 23, 2016 Category: Hematology Authors: Mona Hassanein, Muhamad H. Almahayni, Sameh Gaballa, Syed O. Ahmed, Riad El Fakih Tags: Review Article Source Type: research

Nonadherent Spheres With Multiple Myeloma Surface Markers Contain Cells that Contribute to Sphere Formation and Are Capable of Internalizing Extracellular Double-Stranded DNA
We present phenotypic analysis of free-floating spheres derived from the bone marrow clonogenic aspirate of a multiple myeloma patient. Besides CD73/CD20+/CD45+/CD19dim B cells, these spheres encompass a special subpopulation of cells that can natively internalize extracellular double-stranded DNA and that contribute to the colony assembly. Various cell types found in the free-floating spheres communicate with each other by secreting distinct sets of cytokines. These spheres are capable of forming xenotransplants upon grafting to immunodeficient NOD/SCID mice. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 22, 2016 Category: Hematology Authors: Evgeniya V. Dolgova, Ekaterina Ya Shevela, Tamara V. Tyrinova, Alexandra M. Minkevich, Anastasia S. Proskurina, Ekaterina A. Potter, Konstantin E. Orishchenko, Evgeniy L. Zavjalov, Sergey I. Bayborodin, Valeriy P. Nikolin, Nelly A. Popova, Natalia V. Pron Tags: Original Study Source Type: research